The authors' affiliations are listed in the Appendix.
N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.
In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.
In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab. The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points.
At a median follow-up of 9.4 months, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 months), as compared with a median of 8.1 months in the ofatumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P<0.001). Ibrutinib also significantly improved overall survival (hazard ratio for death, 0.43; P=0.005). At 12 months, the overall survival rate was 90% in the ibrutinib group and 81% in the ofatumumab group. The overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group (42.6% vs. 4.1%, P<0.001). An additional 20% of ibrutinib-treated patients had a partial response with lymphocytosis. Similar effects were observed regardless of whether patients had a chromosome 17p13.1 deletion or resistance to purine analogues. The most frequent nonhematologic adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue, infusion-related reactions, and cough in the ofatumumab group.
Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL. (Funded by Pharmacyclics and Janssen; RESONATE ClinicalTrials.gov number, NCT01578707.).
在慢性淋巴细胞白血病(CLL)或小淋巴细胞淋巴瘤(SLL)患者中,治疗反应持续时间短或存在不良细胞遗传学异常与预后不良相关。我们评估了 Bruton 酪氨酸激酶的共价抑制剂伊布替尼在预后不良风险患者中的疗效。
在这项多中心、开放性、3 期研究中,我们将 391 例复发或难治性 CLL 或 SLL 患者随机分组,分别接受每日伊布替尼或抗 CD20 抗体奥法木单抗治疗。主要终点是无进展生存期的持续时间,次要终点包括总生存期和总缓解率。
在中位随访 9.4 个月时,伊布替尼显著改善了无进展生存期;伊布替尼组未达到中位无进展生存期(6 个月时无进展生存率为 88%),而奥法木单抗组为 8.1 个月(伊布替尼组进展或死亡的风险比为 0.22;P<0.001)。伊布替尼还显著改善了总生存期(死亡风险比为 0.43;P=0.005)。12 个月时,伊布替尼组的总生存率为 90%,奥法木单抗组为 81%。伊布替尼组的总缓解率显著高于奥法木单抗组(42.6%比 4.1%;P<0.001)。另有 20%接受伊布替尼治疗的患者出现淋巴细胞增多的部分缓解。无论患者是否存在 17p13.1 缺失或嘌呤类似物耐药,均观察到类似的效果。伊布替尼组最常见的非血液学不良事件是腹泻、疲劳、发热和恶心,奥法木单抗组是疲劳、输注相关反应和咳嗽。
与奥法木单抗相比,伊布替尼显著改善了先前治疗的 CLL 或 SLL 患者的无进展生存期、总生存期和缓解率。(由 Pharmacyclics 和 Janssen 资助;RESONATE ClinicalTrials.gov 编号,NCT01578707.)。